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1. Introduction
We noted earlier [1] that 1978 was the turning point in current public perception of tradi‐
tional medicine (TM) following the famous WHO declaration at Alma-Ata. That declaration
ushered in a positive attitude that paved the way for the present global popularity of TM,
especially herbal medicine. We noted earlier also [2,3] that whereas herbal remedies are
called dietary supplements in the US, thereby shifting emphasis away from their medicinal
attributes, the Dietary Supplement Health Education Act of 1994 [4], which occasioned the
shift, actually helped to promote herbal medicine in the US, albeit indirectly, through the in‐
novative provision it made for user information [5,6]. A similar situation obtained in Eu‐
rope, where the net effect of the laws and rules passed in 2004 on herbal remedies had been
to promote their production and use [7, 8]. In terms of trade and economics of herbal drugs,
the following fact is notable: Although, Asia contributed only US$ 7.3 billion to herbal world
trade in 1999 [9], by 2005, a mere 6 years, China’s contribution alone rose to US$ 14 billion
[10]. This stupendous growth was due to policies and programmes that favoured herbal
medicine – the cornerstone of Traditional Chinese Medicine (TCM). Similar situations as in
China held sway in Japan, South Korea and the Indian sub-continent, where government
policies also favoured herbal medicine. However, in many developing countries like Niger‐
ia, a totally different picture obtained, not because policies were expressly against herbal
medicine, but in these countries there had been a lingering absence of proper policies and
laws supportive of traditional remedies. Another key fact on the political economy of herbal
drugs is that: Although, about 80% of people in developing countries depended on herbs,
these countries contributed only 7.2% to herbal drug trade in 1999. By contrast, the devel‐
oped nations, where people relied less on herbs, contributed 55.2%. Asia, less Japan and
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South Korea, contributed 37.6%. Equally interesting is the comparison of Brazil with Niger‐
ia. Both are rich in medicinal plants and have high populations that depend substantially on
herbs. But, while herbs contributed an unknown amount to the Nigerian economy in 2007,
in Brazil it contributed US$ 160 million. By contrast, Nigeria’s entire federal budget for
health in 2007 was a mere US$ 800 million [2]. These findings earlier led us [11,12] to con‐
clude that developing countries need strategies that will enhance the regulation of herbal
drugs and promote their trade. The present article is an attempt to enunciate one of such
strategies. It is particularly of note that the superior performance of Brazil in comparison
with Nigeria indicates that with proper policies and strategies, herbs can indeed contribute
substantially to any economy.
2. Methodology: Determinative Review of ISO 9001 and the Mandates of
Nigeria’s and Europe’s DRAs
2.1. ISO 9001:2008 industrial standard – A synopsis
ISO 9001:2008 industrial standard or quality management system (QMS) is a document of
about 30 pages with 8 clauses, published by and obtainable from the International Organ‐
ization for Standardization (ISO), Basle, Switzerland, or from any of its national affiliates.
The standard is designed to be met by any organization that i) needs to demonstrate its
ability to consistently provide product or service that meets both customer and applicable
statutory  and  regulatory  requirements  (collectively  legal  requirements);  ii)  aims  to  en‐
hance  customer  satisfaction  by  effectively  and  continually  improving  its  QMS;  and  iii)
plans to provide continual assurance of  conformity to customer and applicable legal  re‐
quirements. These aims/ approaches (often called “QMS requirements” or “quality proce‐
dures”) are generic and intended to be applicable to all organizations regardless of type,
size and product provided. Wherever any requirement cannot be applied due to the na‐
ture of an organization and its product, such can be considered for exclusion. But wher‐
ever exclusions are made, claims of conformity to the standard are not acceptable unless
such exclusions are limited to requirements within clause 7 of the standard, and such ex‐
clusions do not affect the organization's ability, or responsibility, to provide product that
meets  customer  and applicable  legal  requirements.  ISO 9001:2008  defines  the  minimum
requirements for a well managed organization. In other words, noncompliance to an ISO
9001:2008 requirement puts at risk an organization's ability to consistently and efficiently
satisfy the expectations of its customers/ stakeholders.
2.2. The six QMS requirements or “The Six Quality Procedures”
These procedures or requirements, as one may choose to call them, actually refer to sub-
clause 4.1 (General requirements) under clause 4 (Quality Management System) of ISO
9001:2008. The sub-clause prescribes that organizations shall establish, document, imple‐
ment, and maintain a QMS, and continually improve its effectiveness. To do so means that
the organization shall operate its QMS with a view to carrying out (or meeting) the follow‐
ing six procedures (or requirements): determine the processes needed for the QMS, and their
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application throughout the organization; determine the sequence of the processes and their
interactions; determine the criteria and methods for operating and controlling the processes;
determine and ensure the availability needed resources and supporting information; check,
measure and analyze the processes, where applicable; and implement actions to achieve
planned results and continual improvement of the processes.
Figure 1. NIPRD’s core business in the context of Plan-Do-Check-Act process-based QMS.1
The organization shall manage the processes above in accordance with ISO 9001:2008 re‐
quirements. It shall also define the type and extent of control to be applied to any out‐
sourced process that can affect product conformity to requirements. ISO 9001:2008
specifically notes as follows:
1 Management responsibility corresponds to clause 5 of ISO 9001; while Resource management, Product realization
and Measurement/ analysis/ improvement correspond to clauses 6, 7 and 8 respectively.
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1. Processes needed for the QMS include the processes for management activities (clause
5), provision of resources (clause 6), product realization (clause 7), and measurement,
analysis, and improvement (clause 8).
2. An outsourced process is a process the organization needs for its QMS, and which the
organization chooses to have performed by an external party.
3. Ensuring control over outsourced processes does not absolve the organization of the re‐
sponsibility to conform to customer and legal requirements.
The type and extent of control applied to an outsourced process can be influenced by factors
such as: the potential impact of the outsourced process on the organization's capability to
provide product that conforms to requirements; the degree to which the control over the
process is shared; and the capability of the organization in achieving the necessary control
via the application of sub-clause 7.4 (Purchasing). Philosophically, ISO 9001:2008 is formu‐
lated on the basis of management by objectives (MBO) and draws upon eight quality man‐
agement principles. Ideally therefore, quality assurance covers activities in research,
development, production and documentation. It embraces the rule: "do it right the first
time". It involves regulating the quality of raw materials, the state of production line and
works-in-progress, the product and related management processes. One of the most widely
used paradigms for quality assurance management (QAM) is the “Shewhart cycle”, also
called “PDCA approach”, meaning, “Plan-Do-Check-Act” [13,14]. The foregoing is illustrat‐
ed in Figure 1 using NIPRD QMS processes as an example.
2.3. The eight quality management principles that underlie ISO 9001:2008
Like other ISO standards (Example: ISO 9004 - Managing for Sustained Success), ISO 9001:2008
is based on 8 quality management principles that are aligned with the philosophy and objec‐
tives of most quality award programmes in the world’s most industrialized nations. The 8
principles are associated with the following themes:
1. Customer focus.
2. Leadership.
3. Involvement of people.
4. Process approach to management.
5. System approach to management.
6. Continual improvement.
7. Factual approach to decision making.
8. Mutually beneficial supplier relationships.
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2.4. Key terminologies of ISO 9001:2008
2.4.1. Process approach to management
A process is an activity or operation that receives inputs and converts them to outputs. Prac‐
tically all activities or operations involved in generating a product or providing a service are
processes. For an organization to function, it must define and manage several inter-linked
processes. Most often, the output of one process becomes the input into the next process.
The systematic identification and control of the various processes employed within an or‐
ganization, and the interactions between such processes, is termed “process approach” to
management. Thus process approach to management is a way of obtaining a desired result,
by controlling activities and related resources as a process. Process approach is a key ele‐
ment of all ISO 9000 standards, including ISO 9001:2008.
2.4.2. System approach to management
System approach to management is based on the premise that the efficiency and effective‐
ness with which an organization achieves its quality objectives are contributed and en‐
hanced by identifying, understanding and managing all the interrelated processes within
the organization as a system
2.4.3. Quality policy
Quality policy is a formal statement from the management of an organization that is linked
to the nature of its business and its plans to meet the needs of its customers/ stakeholders.
The policy is designed to be understood and followed at all levels and by all staff.
2.4.4. Quality objective
Quality objective is the factual or tangible basis upon which quality policy and plans for im‐
plementing the quality programmes of an organization are built. Quality objective should be
SMART (ie: specific, measurable, achievable, realistic and time-bound). Each staff of the or‐
ganization is expected to work towards measurable objectives.
2.4.5. Decision
Decision simply means the selection of one or more options from a multitude of options in
tackling a given organizational task. As far as the QMS is concerned, an organization should
make SMART decisions based on recorded data. An example of a SMART decision is: The
QMS must be audited and evaluated regularly for conformance and effectiveness, so as to
assure quality and continual improvement.
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2.4.6. Traceability
Traceability is concerned with and refers to the fact that typically, recorded data are meant
to show how and where raw materials and products were processed, in order to allow prod‐
ucts and problems to be traced to their sources.
2.4.7. Product realization
Product realization refers to the scenario in which, when developing a new product, an or‐
ganization plans the stages of development, with appropriate testing at each stage. The or‐
ganization tests and documents whether the product meets design requirements, legal
requirements, and user or customer needs.
2.4.8. Quality plan
Quality plan refers to a document specifying the QMS processes (including the product real‐
ization processes), and the resources to be applied to a specific product or project.
2.4.9. Monitoring and measurement
Monitoring and measurement refer to the scenario in which an organization must regularly re‐
view its performance through meetings and internal audits, and determine whether the QMS
is working and what improvements can be made. The organization must have a documented
procedure for internal audits and a procedure for dealing with past problems and potential
problems. It must keep records of these activities and the resulting decisions, and monitor their
effectiveness. It must have documented procedures for dealing with actual and potential non-
conformances (problems involving suppliers, customers, or internal problems).
2.4.10. Continual improvement
Continual Improvement refers to the scenario in which an organization 1) makes sure no
customer uses a bad product, 2) determines what to do with a bad product, 3) deals with the
root cause of problems, and 4) keeps records to use as a tool to improve the QMS.
2.4.11. Customer requirements
Customer requirements refer to the attributes that the buyer of a product (or user of a serv‐
ice) wants. The core business of an organization is to determine customer requirements and
to meet them, in accordance with sub-clause 5.2 (Customer focus).
2.4.12. Drug Regulatory Agencies (DRAs)
Drug regulatory agencies (DRAs) are organizations set up by the State on behalf of the gen‐
eral public with a Mandate to regulate drugs and related products and services. The Man‐
date of some DRAs may include production and distribution of certain goods like vaccines
and orphan drugs. Either the State or the general public can be regarded as customer, stake‐
holder or shareholder. DRAs like all other organizations must have a system for communi‐
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cating with customers or stakeholders about product information, inquiries, contracts,
orders, feedback, and complaints. All DRAs are “service providers” but some produce and
even distribute certain specific items, as mentioned above. Nigeria’s National Agency for
Food and Drug Administration and Control (NAFDAC) is a national DRA, while the Euro‐
pean Medicines Evaluation Agency is a regional DRA.
2.4.13. Mandate
Mandate is a piece of legislation or instruction from a constituted authority to another con‐
stituted authority or body to carry out a named task. DRAs are mandated by the State to
regulate drugs and health related products.
2.5. The new industrial revolution and the aim of this chapter
It is well established that the high state of development in the chemical/ pharmaceutical in‐
dustrial sector in the US, Japan, South Korea, Britain, Germany and other European coun‐
tries owes much to the powerful synergy between regulatory legislations, industrial
standards and a focused political will. It is also manifest that the rapid, all-round industrial
revolution in China in the past decade or so owes much to China’s embrace of ISO stand‐
ards, especially ISO 9001, as shown in Table 1 after a recent [15].
Country Ranking No. certificates Pertinent remark
China 1 257,076 Relies mostly on ISO standard.
Italy 2 130,066 Relies mostly on ISO standard
Japan 3 68,484 Relies only partly on ISO standard
Spain 4 59,576 Relies substantially on ISO standard
Russia 5 53,152 Relies substantially on ISO standard
Germany 6 47,156 Relies only partly on ISO standard
UK 7 41,193 Relies only partly on ISO standard
India 8 37,493 Relies substantially on ISO standard
South Korea 9 28,935 Relies substantially on ISO standard
US 10 23,400 Relies only partly on ISO standard
*Source ISO Survey 2009 [15]. Most countries have their own national standards in addition to ISO
standards. For example the UK is well known for its industrial standards pre-sufixed by BSI (British
Standards Institution).
Table 1. The top 10 countries in ISO certification in 2009.
It must be stated that countries like Japan, Germany, Britain and US use their own national
standards in addition to those of ISO. Based on the foregoing, we state that the specific aim
of this article is: To examine the QMS requirements of ISO 9001:2008 and the requirements
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for regulating herbal drugs in Nigeria (a developing economy) and Europe (a developed
economy), with a view to devising a framework that will better regulate herbal drugs and
facilitate their trade worldwide. Such a framework will greatly benefit developing countries
like Nigeria that are yet to benefit optimally from their comparative advantage in the abun‐
dance of spices, herbs and medicinal plants. In addition, marketers and users of herbs in
consumer nations like the US, Canada, Germany, UK and France, where consumption now
runs in to billions of US dollars, will also profit greatly from an improved and regularized
world trade in herbs.
3. Results & discussion: A Framework for Efficient Herbal Drug
Regulation (HDR)
3.1. Justification for establishing national or regional DRAs
Most or all countries have a national or regional agency that regulates the production, distri‐
bution and use of drug products. The process of regulation commences with the registration
of the producer, the product, the distributor and in some cases the user. In some countries
drugs, foods and dietary supplements are regulated by the same body (eg: Nigeria’s NAF‐
DAC and US-FDA). The EU’s EMEA however regulates only drug products. States or re‐
gions need to have DRAs in order to ensure order in the production, distribution and use of
drugs. Without DRAs utter chaos and pandemonium will result in production (eg: manufac‐
turers will do as they please without a uniform control), distribution (distributors and sup‐
pliers will do as they choose without a uniform order) and use (prescribers and users will do
as they think without a uniform regime), which would allow incidences of counterfeit and
expired drugs in drug distribution chain, drug abuse and emergence of drug resistant disor‐
ders, especially infective conditions like malaria and TB.
3.2. Comparative analysis of Nigeria’s and EU’s requirements for herbal drug regulation
A careful scrutiny of the requirements for registering and regulating herbal drugs in Europe
and in Nigeria reveals their basic similarity, as shown in Table 2.
European Union (EU) – regulated by EMEA Nigeria – regulated by NAFDAC
Type of data Details of data required Regulatory
aspect
Requirement
Product
information:
Summary of
product
characteristics
These include: name, strength, dosage
form, list of excipients, shelf life, posology, indications,
contraindications, and special precautions. These are used as basis
for inserts or advertisement, which must undergo a process called
“readability”.
Legal status of
applicant -
manufacturer
or marketer
Applicant must be certified by the Corporate
Affairs Commission as a business. A marketer
must show evidence of Power of Attorney.
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European Union (EU) – regulated by EMEA Nigeria – regulated by NAFDAC
Type of data Details of data required Regulatory
aspect
Requirement
Quality control
data:
Refer to GMP
requirements
for production.
These include: production must be in a GMP compliant, product
must be produced with validated formula and method, there must
be a product specification, stability studies must be carried out in
the container proposed for marketing for purposes storage/ shelf-
life, and dossiers must be provided for starting materials and
finished product.
Analytical status of the
product for
registration.
The product must have: certificate of
analysis, dossier containing data on
ingredients, method of analysis, stability,
dosage and safety precautions.
Safety data
requirements
The data may be assembled from: animal
or human studies, review of potential drug-drug interactions, side
effects and contraindications. Others include:
recognized monographs, data special
groups - children, the elderly and mothers.
Pre-registration
inspection of premises.
Manufacturing, storage and distribution
premises must be GXP compliant. Marketers
must provide convincing evidence of GXP
Traditional use
evidence
Evidence that the product has been in use
as medicine for 30 years or more (the last
15 must be in the EU. Notably, there is no requirement to prove
efficacy (De Smet, 2005). 
Post marketing
surveillance plan/
report
Applicant may be required to provide a plan
for reporting on the use of the product and
of any adverse reactions.
- - Others, such as fees
and
waivers.
Fees are required at several stages of the
registration but waivers are not expressly
stated, thereby negating the concept and
need for transparency (see Table 3 for extra
requirements).
*The Table was drawn based on data gathered from references including Goldman [5]; De Smet [7, 8]; Ann
Godsell Regulatory [16]; and various NAFDAC leaflets, including Akunyili [17]. Note that the requirements for
registration in Nigeria are not necessarily less tasking, but their lack of explicitness can be a booby trap and a
leeway for non-transparency. The necessity for explicitness and transparency is very important because some
years ago the Director General of China’s drug regulatory agency was sentenced to death for alleged corrupt
practice [18]. In 2000 the entire Management of NAFDAC was sacked in similar grey circumstances.
Table 2. Requirements for herbal registration compared between EU and Nigeria.
But, while the EMEA approach is technically more explicit, though not necessarily more ex‐
erting than NAFDAC’s, the latter is administratively much more cumbersome, and therefore
more liable to inefficiency and abuse. Table 3 shows the extra bureaucratic demands of
NAFDAC. We stated earlier that, although, 80% of people in developing countries like Ni‐
geria depended on herbs, these countries contributed only 7.2% to herbal drug trade in 1999.
By contrast, the developed nations, where people relied less on herbs, contributed 55.2%.
This scenario is explained by the fact herbal drugs are better regulated in developed regions
like the China, India, Japan and South East Asia, the EU and North America [2].
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3.3. Justification for selecting ISO 9001:2008 for this study
Although most of the OECD countries and other highly industrialized economies, where
herbal drugs are well regulated, have their own national standards, all do embrace ISO
standards, especially ISO 9001:2008. For example, the British Standards Institution (BSI) is
well known and widely adopted in many other countries worldwide, and although interna‐
tional in application, such national standards do not bear the tag “international”. By con‐
trast, the ISO family of standards bear the tag “international”. ISO 9001:2008 is an
international standard designed to address systemic change (ie: a change that affects an or‐
ganization as a whole). The global popularity of ISO 9001:2000 - the predecessor of ISO
9001:2008, is attributable to the following factors: a) major purchasers require their suppliers
to hold ISO 9001 certification [15, 19]; b) studies indicate significant financial benefits for or‐
ganizations certified to ISO 9001 [19,20]; and c) similar superior operational performance of
ISO certified firms has been severally confirmed [21-24]. As just noted, ISO 9001:2008 is an
update of ISO 9001:2000, and we have selected it for this study by reason of its popularity
and versatility, and because it is a process-based QMS that addresses systemic change affect‐
ing whole organizations like a national or regional drug DRA, like Nigeria’s National Agen‐
cy for Food and drug Administration and Control (NAFDAC), the US Food and Drug
Administration (US-FDA) and the European Medicines Evaluation Agency (EMEA).
S/No Extra requirement Remark
1 Five (5) copies of the product dossier. Probably unreasonable
2 Three (3) packs of the products samples. Probably reasonable
3 Notarized original copy of the duly executed Power of
Attorney from the product manufacturer.
Clearly unreasonable for all
categories of applicants
4 Certificate of Manufacture issued by the competent
health or regulatory authority in country of origin and
authenticated by the Nigerian Mission in that country.
Where there is no Nigerian mission, The British High
Commission or an ECOWAS country Mission will
authenticate.
Probably unreasonable for all
categories of applicants
5 If contract-manufactured, Contract Manufacturing
Agreement, properly executed and notarized by a
Notary Public in the country of manufacture.
Clearly unreasonable for all
categories of applicants
6 Current World Health Organization Good
Manufacturing Practice Certificate for the
manufacturer, authenticated by the Nigerian Mission.
Clearly unreasonable for all
categories of applicants
7 Certificate of Pharmaceutical Products (COOP) duly
issued and authenticated.
Clearly unreasonable for all
categories of applicants
8 Current Superintendent Pharmacists license to
practice issued by the Pharmacists Council of Nigeria (PCN).
Only probably reasonable
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S/No Extra requirement Remark
9 Premises Registration License from PCN Only probably reasonable
10 Certificate of Registration of brand name with
trademark registry in the Ministry of Commerce here
in Nigeria; Letter of invitation from manufacturer to
inspect factory abroad, stating full name and location
of plant.
Probably unreasonable for all
categories of applicants
11 The applicable fee payable only if documents are
confirmed to be satisfactory
Likely to be abused if the
amount is high. The fee should
be a token amount paid by all
applicants
12 Nutraceuticals, medical devices and other regulated
drug products have similar requirements, with minor
variations. Specific details can be obtained from
NAFDAC.
A sketch of the minor variations
should be provided in print no
matter how brief. Any
information provided by
NAFDAC should be printable
for sake of transparency
*The information on NAFDAC were drawn from leaflets and NAFDAC’s website (2010): www.nafdacnigeria.org/ The
remarks are informed by current affairs and public perception of NAFDAC’s role and activities including the wholesale
reorganization of its Management in 2000.
Table 3. NAFDAC’s extra requirements for registering herbal medicines.
3.4. A systematic review of the eight clauses of ISO 9001:2008 in relation to DRAs
3.4.1. A synopsis of the Mandate of DRAs and the eight clauses of ISO 9001:2008
ISO 9001:2008 is the most widely used QMS standard, with over a million certificates issued
worldwide. Alas, it was revealed at the SON-NIPRD course in 2011, that only two public in‐
stitutions in Nigeria have ISO 9001 certification! Yet, as stated earlier, ISO 9001:2008 defines
the minimum requirements for a well managed organization. The standard is published by
the International Organization for Standardization (ISO), Basle, Switzerland. National ac‐
creditation bodies like the Standards Organization of Nigeria (SON) provide accreditation to
registrars who issue the ISO 9001 certificates to those they audit. ISO 9001:2008 is set out in
eight clauses designated clauses 1 to 8. The structure and salient points/ directing principles
of the clauses are tabulated below. A copy of ISO 9001:2008 is a prerequisite for this study.
Similarly required, is a grasp of the requirements for registering and regulation herbal drugs
in a developed economy like Europe; and in a developing country like Nigeria, as depicted
in Table 2. It is well known that herbal drugs are better regulated in the developed than in
developing countries. Table 3 suggests that undue bureaucracy or needlessly cumbersome
requirements can hinder efficient regulation. Tables 4-13 show the structure and salient
points/ directing principles of the 8 clauses.
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Clause Title and subtitles, with remarks Salient points/ directing principles/ application to DRAs
1 1. Scope
1.1 General
1.2 Application
ISO 9001:2008 can be used to establish, and to update a DRA’s QMS. A DRA, like other parastatals or
private organizations must consider its unique operational environment and the dynamics and risks
associated therewith.
2 2. Normative references
(eg: ISO 9000:2005 is devoted to QMS
Fundamentals and Vocabulary; and ISO
9004:2009 is devoted to Managing for
Sustained Success)
A normative reference implies, unless otherwise stated, that the most recent versions of the separate
documents should be referenced. DRAs would benefit immensely from such key references and
compendia such as the International Pharmacopoeia and others like the BP and USP, and the WHO
manual on Quality Control Methods for Medicinal Plant Materials.
3 3. Terms and definitions
(see section 2.4 of this article on “Key
terminologies of ISO 9001:2008)
The term “product” may also mean “service”. “Legal requirements” means “statutory and regulatory
requirements”. Most DRAs are service providers only, while others may produce and distribute certain
specialized health products.
*The Table is to be studied side by side with the contents of ISO 9001:2008 and Table 2, which is on regulatory re‐
quirements of DRAs.
Table 4. Clauses 1-3 of ISO 9001:2008 in relation to DRAs.
Clause Title and subtitles, with remarks Salient points/ directing principles/ application to DRA
4 4. Quality Management System (QMS)
4.1 General requirements
4.2 Documentation requirements:
4.2.1 General – QMS documents must
include: quality policy, quality objective,
quality manual, documented procedures/ records
specified by ISO 9001:2008, and documents/ records
determined by the organization to be relevant for
effective planning, operation and control of the QMS.
4.2.2 Quality manual – this should
include the scope of the QMS, SOPs and a description of
the QMS processes.
4.2.3 Control of documents - the documents required
by the QMS must be established and controlled. This
means that SOPs are to be established to define the
controls needed.
4.2.4 Control of records – records are a
special type of documents and must be established and
controlled. Here too, SOPs
are to be established to define the controls needed.
Note:1) A document is a piece of written, printed, or
electronic matter that provides information or evidence.
It may or may exist
Clause 4.1 implies that the DRA must identify, manage and document the processes that
make up its QMS – ie: the DRA must address the so called “Six Quality Procedures” and
generate relevant documents, including: 1) quality manual, 2) quality policy, 3) quality
objective, 4) process flowchart, and 5) work instructions. The DRA can achieve this by using a
management strategy called “process approach”, which means that it must manage: 1) the
processes that make up its organization, 2) the interaction between these processes, and 3)
the inputs and outputs that glue these processes together. The quality manual should: 1)
describe how the QMS processes interact; 2) define the scope of the QMS (it should explain
any reductions in the scope of the QMS and justify all exclusions/ reductions); and 3)
document all procedures in the QMS or refer to them. It is most crucial that the DRA
prepares, establishes and maintains a quality manual.
The DRA must establish SOPs to define the controls needed: 1) to approve, review, update
and re-approve documents prior to use; 2) to ensure that changes, current status, relevant
versions of documents are identified; and 3) to prevent the unintended use of obsolete
documents. The DRA must establish records to provide: 1) evidence that operations conform
to QMS requirements; and 2) evidence that operations of the QMS are effective. Records
must be ensured to be legible, readily identifiable and retrievable.
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Clause Title and subtitles, with remarks Salient points/ directing principles/ application to DRA
in a permanent form. 2) A record is a permanent
document of something that is
kept for evidence or information. It specifically bears the
history of events or arrangements, and is preserved in a
lasting form.
*The Table is to be studied side by side with the contents of ISO 9001:2008 and Table 2, which is on regulatory re‐
quirements of DRAs.
Table 5. Clause 4 of ISO 9001:2008 in relation to DRAs.
Clause Title and subtitles, with remarks Salient points/ directing principles/ application to DRA
5 5 Management Responsibility
5.1 Management commitment
5.2 Customer focus – the organization must ensure that
its purpose/ focus (inclusive of customer/ stakeholder
requirements) is understood and determined.
5.3 Quality policy – this should be:
1) appropriate to the purpose of the organization; 2)
focused on meeting requirements and continual
improvement; 3) used as a framework for quality
objectives; 4) publicized and understood at appropriate
levels; and
5) reviewed for continuing suitability .
5.4 Planning
5.4.1 Quality Objectives
5.4.2 QMS Planning
5.5 Responsibility, Authority, and
Communication
5.5.1 Responsibility and Authority
5.5.2 Management Representative
5.5.3 Internal Communication – it is crucial that the
organization ensures that appropriate communication
processes regarding the effectiveness
of the QMS are established and implemented.
5.6 Management Review
5.6.1 General
5.6.2 Review Input – includes audit results, public
feedback, process performance, status of preventive/
corrective action, follow-up from previous management
review,
The DRA must be committed to developing and implementing a QMS, as well as, a commitment
to continually improve the effectiveness of the QMS. The DRA can do this by 1) communicating
the importance of meeting “legal and customer requirements”; 2) establishing a quality policy
and quality objectives; 3) conducting management reviews; and 4) by ensuring the availability of
necessary resources. The “legal and customer requirements” of a DRA are implicit in its Mandate
– which may be an act, law or decree. In planning, the DRA must 1) ensure that quality objectives
are established at the relevant functions and levels within the Agency; 2) ensure that quality
objectives are measurable and consistent with the quality policy; and 3) ensure that planning for
the QMS meets the general requirements (clause 4.1) and quality objectives (clause 5.4.1), as
well as, maintains the integrity of the QMS.
In as much as operations must be carried out the DRA must ensure that the responsibilities and
authorities for such are defined and communicated appropriately. It is essential that a member
of top management, irrespective of other duties, be appointed (as Quality Manager) and given
the responsibility to: 1) ensure that the needed processes are established, implemented, and
maintained; 2) report to top management on the performance of the QMS; 3) report to top
management on any need for improvement; and 4) ensure the promotion of awareness of
Agency’s Mandate. Most DRAs have a public relation office.
For a DRA to be effective it must review its QMS at planned intervals to: 1) ensure an effective
QMS; 2) assess possible opportunities for improvement; 3) evaluate the need for any changes;
and 4) consider the need for changes to the policy and objectives. The DRA must of course
maintain records of reviews as per clause 4.2.4. For a DRA, the inputs for review must include
information on: 1) results of audits; 2) feedback from government and the public, eg - incidences
of counterfeit drugs; 3) status of preventive and corrective actions, eg – incidences of drug
abuse; 4) follow-up actions from earlier reviews; 5) changes that can affect the QMS; and 6)
recommendations for improvement.
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changes that can affect the QMS, and recommendations
for improvement.
5.6.3 Review Output - includes decisions/ actions related
to: 1) improvement of the QMS; 2) improvement in
meeting Mandate;
and 3) resource needs
*The Table is to be studied side by side with contents of ISO 9001:2008 and Table 2, which is on regulatory require‐
ments of DRAs.
Table 6. Clause 5 of ISO 9001:2008 in relation to DRAs.
3.4.2. The immediate historical antecedent of NAFDAC and the continuing relevance of ISO 9001
Nigeria’s NAFDAC was created by decree in 1992/93 following the ethylene glycol disas‐
ter  of  1991/92  in  Langtang  General  Hospital,  Plateau  State,  where  ethylene  glycol  was
used in the place of propylene glycol in preparing paracetamol elixir. The glycol had been
purchased  from  a  hitherto  popular  pharmacy  shop  located  at  Masalachin-Jumai  Street,
Jos.  Prior  to 1992/93,  a  department in the Federal  Ministry of  Health handled food and
drug administration in Nigeria. Alas, in 2009 another ethylene glycol disaster occurred in
Lagos. In this latter disaster a hitherto popular brand of paediatric mixture (“My Pikin”)
was  found  to  contain  ethylene  glycol  that  had  been  purchased  from  an  unregulated
source. It is important to note that whereas the glycol implicated in the Lantang disaster
was purchased from pharmaceutically regulated source, the glycol in the case of the La‐
gos disaster was purchased from a company that dealt in industrial chemicals associated
with automobiles and cooling systems. The occurrence of this kind of disaster within less
than two decades is matter of concern that calls for a more efficient programme for regu‐
lating drugs and industrial  chemicals in developing countries.  The US-FDA after  whose
image  and  likeness  NAFDAC was  created  is  known for  efficiency  mostly  because  it  is
supported by proper  laws and strong institutions.  Better  laws and stronger  institutions,
including DRAs, are required to avoid or minimize this kind of disaster as seen in Niger‐
ia. It seems instructive to mention the “Tylenol case” in the US, and how that case led to
a new legislation. Between late September and early October 1982, seven persons in Chi‐
cago  died  after  taking  capsules  of  Tylenol  (a  brand  of  paracetamol),  to  which  cyanide
crystals had been added. The crystals had apparently been introduced into the capsules
by someone who had removed bottles  of  Tylenol  from several  drugstores  and then re‐
placed  them  on  the  shelves.  It  took  an  intensive  investigation  by  a  team  of  over  100
agents, including FDA staff, to discover the mischief, which led to a 1982-legislation that
required all over-the-counter drugs and medicines sold in the county (and later elsewhere
in the US and beyond) carry manufacturers'  seals which broken would be obvious.  The
rapid conclusion of the investigation led by the Illinois Attorney General himself (Tyrone
C. Fahner) and the dispatch with which the new law was issued collectively testify to the
inner workings of strong institutions – which developing nations lack.
Latest Research into Quality Control96
Clause Title and subtitles, with remark Salient points/ directing principles/ application to DRAs
6 6 Resource management
6.1 Provision of resources
6.2 Human resources
6.2.1 General
6.2.2 Competence, Training, and
Awareness
6.3 Infrastructure
Like any other public outfit the DRA must determine,
provide, and maintain infrastructure like buildings,
workspace and associated utilities, and essential support
services.
6.4 Work Environment
“Work environment” implies conditions under which work
is performed, and includes physical aspects like weather
and noise pollution.
The DRA must determine and provide the resources needed: 1) to implement, maintain and
continually improve the effectiveness of its QMS; and 2) to enhance the fulfilment of its
Mandate.
By virtue of its role as a highly specialized agency, the DRA must ensure that all staff
irrespective of department whose work can impact DRA’s Mandate are competent based on
appropriate education, skills, experience and abide by their professional ethics.
This implies that the DRA must: 1) determine the competency of staff; 2) provide training as
needed; 3) evaluate the effectiveness of the actions taken on training and skills acquisition ; 4)
inform staff of their relevance within the QMS; 5) ensure staff know their contributions to
achieving quality objectives; and 6) maintain staff records of education, training, skill, and
experience in accordance with clause 4.2.4.
The DRA must, of course, provide appropriate work environment for all staff whose work
impacts the DRA’s Mandate.
*The Table is to be studied side by side with contents of ISO 9001:2008 and Table 2, which is on regulatory require‐
ments of DRAs.
Table 7. Clause 6 of ISO 9001:2008 in relation to DRAs.
3.4.3. The making of stronger DRAs and the need for clearer demarcation of responsibilities
In most countries where DRAs are not a department of the Ministry of Health, they exist as
a parastatal or as a special department within the Ministry (as in Japan), with conditions of
service being slightly more favourable than in the rest of the Ministry. The idea is to give
special incentives to the staff on account of hazards perceived to be peculiar to the job. In
Nigeria, NAFDAC is well housed both at the federal and state levels and the staff earn about
the same remuneration as the universities and research institutes. In most countries the
DRAs have well equipped offices and laboratories, and those DRAs that produce and dis‐
tribute goods are equipped with the necessary plant and storage facilities.
3.4.4. The inevitability of confusion in the absence of regulatory standardization
In Nigeria, NAFDAC previously handled certain aspects of manufacture/ distribution of
vaccines until certain developments (or rather controversies over quality/ effectiveness of
polio vaccines during the late 1990s/ early 2000s) led, first to the creation of a National Pro‐
gramme on Immunization (NPI); and latter to the transfer of the same functions from NPI
back to the Federal Ministry of Health. It is obvious from the foregoing that institutions like
NAFDAC and NPI would have performed better had they been certified. It seems also that
one of the keys to ending the cycle of poverty and underdevelopment in some countries is to
ensure that elite institutions like the DRAs are certified to appropriate ISO standards. Certif‐
ications of agencies like the Health Insurance Scheme and the Pension Commission will def‐
initely reduce perceive current levels of corruption in such institution.
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7 7 Product realization
7.1 Planning of product
realization Product realization typically implies that
manufacturers 1) plan and develop the QMS processes
needed for product realization; 2) keep the planning
consistent with other requirements of the QMS; 3)
document the plan
in a suitable form; and 4) determine through the planning,
the following: a) quality objectives and product
requirements; b) need for processes, documents, and
resources; c) verification (establishment of truth/
confirmatory evidence), validation (formal registration/
obtainment of official sanction), monitoring, measurement,
inspection, and test activities; d) criteria for product
acceptance; and e) records
providing evidence that the processes and resulting product
meet requirements. Since DRAs regulate manufacturers they
too must be acquainted with clause 7. NOTE 1: Recall that
“quality plan” (2.4.8 of this article) is a document specifying
the processes, and the resources to be applied to a specific
product, project, or contract.
NOTE 2: An organization can apply the requirements of sub-
clause 7.3 (vide infra) to the development of product
realization processes7.2 Customer-Related Processes
7.2.1 Determination of
Requirements Related to the
Product
7.2.2 Review of Requirements
Related to the Product
7.2.3 Customer Communication
The intensity and scope of communication depends on the
product and the associated
mandate. Thus the DRA must determine and implement the
necessary arrangements for communicating with
stakeholders
on aspects like 1) product information; 2) inquiries and
contracts; 3) customer/ stakeholder feedbacks -positive or
negative
Some DRAs produce/ store/ distribute specialized and non-profit products like vaccines and
orphan drugs. For such, all aspects of clause 7 apply. The DRAs of developed economies
concentrate on regulating manufacturers, distributors and use of products. Different
processes are involved in drug regulation but these often have some aspects in common.
For example, the process of registering a manufacturer and that of registering a product are
essentially the same, but they differ in their aims, point of action, who by, and so on. Some
of the processes involved in “planning of service realization”, which is the core business of a
typical DRA, require a wide range of differing concepts, technicalities, approaches,
specializations, and so on. For example, although the technical aspects of producing tablets
of aspirin, diazepam, B-complex, erythromycin, and orphan drugs may be similar, the modes
of their regulation and distribution are different. Given the involved Mandate of DRAs,
different strategies must be developed to grapple with the differing nuances and intricacies
associated with the regulation of the five products. Typically, questions that have answer
buried in culture/ society rather than the lab do arise in drug regulation. Why, for example,
despite the similarities between NAFDAC and EMEA, it is impossible to buy erythromycin or
diazepam over-the-counter in Europe but not in Nigeria? To what extent do political, social
and economic factors affect “planning of service realization” in different social
environments? It well known that regulatory strategies that work in Europe often fail to
work outside despite obvious legislative similarities between nations.
The customers/ stakeholders of a typical DRA are the general public, manufacturers,
suppliers and the government. DRAs that engage in production and distribution must
determine customer requirements, which invariably include specified and unspecified but
desirable attributes. Such DRAs must also determine the legal requirements applicable to
the product. Other desirable requirements, including post-delivery activities like
maintenance services, may be considered. DRAs that produce or distribute would normally
review the product requirements before committing to supply in order to: 1) ensure that
product requirements are defined; 2) resolve any requirements differing from those
previously expressed; and 3) ensure its ability to meet the requirements. In the same vein
when a DRA plans a regulatory strategy or legislation the plan should be graduated and
made reasonable to its purpose and scope and with reference to the operating
socioeconomic environment. The DRA must maintain the results of reviews, and any
subsequent follow-up actions in accordance with 4.2.4. When the requirements are not
documented, they must be confirmed before acceptance. But if product requirements are
changed, the DRA must ensure relevant documents are amended and relevant personnel
are made aware of the changed requirements.
NOTE: In some situations a formal review is impractical for each order. In such cases reviews
can cover relevant product information such as catalogues or adverts.
*The Table is to be studied side by side with contents of ISO 9001:2008 and Table 2, which is on the regulatory re‐
quirements of DRAs.
Table 8. Clause 7 of ISO 9001 in relation to DRAs (Product planning and Customer-Related processes).
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7 7.3 Design and Development
7.3.1 Design/ Development Planning
DRAs that produce or distribute must plan and control product
design/ development. They must determine 1) the stages of
design/development; 2) appropriate testing, review and validation
for each stage; and 3) responsibility/authority for design/
development.
7.3.2 Design /Development Inputs
In designing/ developing a physical good or a service, the DRA
must determine the needed inputs and keep records as per 4.2.4.
The inputs must include: 1) functional and performance
requirements; 2) applicable legal requirements; 3) applicable
information derived from similar designs; and 4) requirements
essential for design and development.
7.3.3 Design/ Development Outputs
Where applicable, DRAs must
document the outputs of the design/ development process in a
form suitable for verification against the inputs to the process. The
outputs must 1) meet or match design and development input
requirements; 2) provide information
for purchasing, production and service; 3) contain or reference
product acceptance criteria; 4) define essential characteristics for
safe and proper use; 5) be approved before their release
7.3.4 Design/ Development Review
7.3.5 Design/ Dev. Verification
7.3.6 Design/ Dev. Validation
Validation activities are performed in accordance with 7.3.1 to
confirm that the resulting product is capable of meeting the
requirements for its specified application or intended use.
7.3.7 Control of Des./ Dev Changes
For either physical goods or policy,
DRAs must 1) identify design and development changes and
maintain records as per 4.2.4; 2) review, verify, validate and
approve changes before implementation; 3) evaluate the changes
in terms of their effect on constituent parts (raw material) and
products (or policies) already delivered (or implemented).
The same principle followed in planning a physical product is followed in planning a
service. The interfaces between the different groups involved must be managed to
ensure effective communication/ clear assignment of responsibility. Design and
development review, verification and validation have distinct purposes. They can be
conducted and recorded separately or in any combination, as the DRA deems suitable
for the product or the type of service.
A DRA would review the selected inputs for adequacy and resolve any incomplete,
ambiguous, or conflicting requirements. Examples of application inputs include: (1
applicable information derived from similar designs; and (2 requirements essential for
design and development. If a DRA is designing a policy to curb drug abuse in a
particular locality, useful inputs for the design would include statistics like 1) the age,
gender and occupation of abusers; 2) the type of drugs abused; and 3) the success
rate of similar policies elsewhere. NOTE: Information for production and service can
include details for product preservation.
A DRA must perform systematic reviews of design and development at suitable stages
in accordance with planned arrangements (7.3.1) so as to: 1) evaluate the ability of
the results to meet requirements; and 2) identify problems and propose necessary
actions. Reviews must include representatives of the functions concerned. Results of
reviews and subsequent follow-up actions must be maintained as per 4.2.4. A DRA
would perform design and development verification in accordance with 7.3.1 to
ensure that output meets the design and development input requirements; and
maintain the results of such verification and subsequent follow-up actions. When
practical and desirable, validation must be completed before delivery or
implementation of the product. Results of the validation and of subsequent follow-up
actions must be maintained as per 4.2.4. Just as some DRAs produce or distribute
physical products, some DRA have their own testing facilities while others contract
out such tests. Thus the purchase needs of DRAs differ with their Mandate. However,
whenever purchasing is indicated the DRA must 1) ensure that purchased items
conform to specified purchase requirements (Note: The type and extent of control
applied to the supplier and purchased product depends upon the effect of the
product on the subsequent realization processes or the final product); 2) evaluate and
select suppliers based on their ability to supply goods in accordance with
requirements; 3) establish the criteria for selection, evaluation, and re-evaluation; and
4) maintain the results of such evaluations and subsequent follow-up actions in
accordance with sub-clauses 4.2.3 and 4.2.4.
*The Table is to be studied side by side with contents of ISO 9001:2008 and Table 2, which is on the regulatory re‐
quirements of DRAs.
Table 9. Clause 7 of ISO 9001:2008 in relation to DRAs (Design and Development).
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3.4.5. Some causes and signs of a malfunctioning DRA
Once the staff recruitment system can be skewed to favour persons, a serious non-compli‐
ance exists.  Once the purchase processes can be demonstrated to have vested interest,  a
serious flaw exists in the QMS. Once there is a convincing evidence of maladministration,
arbitrary  treatment  of  personnel  or  executive  high  handed,  a  serious  condition  against
performance exists.
Clause Title and subtitles, with remarks Salient points/ directing principles/ application to DRAs
7 7.4 Purchasing
7.4.1 Purchasing Process
7.4.2 Purchasing Information
All organizations irrespective of type of business will have
cause to purchase a multitude of goods for the business. If
such goods are to meet their purposes criteria and
processes must be developed their purchase. Thus
purchasing information should contain: 1) explicit
description of goods: 2) approval criteria for the goods,
procedures, processes, and associated equipment or
accessories; and 3) profession/ qualification of staff
associated with the goods.
7.4.3 Verification of Purchased Product
7.5 Production and Service Provision
7.5.1 Control of Production and
Service Provision
A producing/ distributing DRA must plan and carry out
production and service provision under controlled
conditions, which include: 1) availa-
bility of data on needed inputs; 2) availability of necessary
work instructions; 3) availability/ usability of essential
equipment; 4) availability/ usability of monitoring and
measuring equipment; 4) ability to implement monitoring
and measurement
activities; and 5) ability to implement product release,
delivery, and post-delivery activities. DRAs that
do not produce/ distribute must nevertheless have
possess the ability to ensure that manufacturer/
distributors have all it takes to adequately meet
QMS requirements.
7.5.2 Validation of Processes for
Production and Service Provision
7.5.3 Identification and Traceability
7.5.4 Customer Property
Whether a DRA produces/ distributes it will have cause to purchase various items of commerce
hence QMS requirements for purchases are required. Like other organizations a DRA would
require and ensure the adequacy of the specifications of items to be purchased before
communicating the purchasing information to the supplier. Typically a DRA would establish
and implement inspection or other necessary activities for ensuring that purchased goods
meet the specified purchase requirements. If a DRA or its customers/ stakeholders propose to
verify a good or service at the supplier’s location, the intended verification arrangements/
method must be stated in the purchasing information.
It is typically pertinent that a DRA 1) validates any production or service provision that
subsequent monitoring cannot verify. Such validations include processes where deficiencies
may become apparent only after product use or service delivery; 2) demonstrates through the
validation the ability of processes to achieve the planned results; and 3) establishes validation
arrangements including, as applicable: a) criteria for process review and approval, b) approval
of equipment, c) qualification of staff, d) use of defined methods and procedures, e)
requirements for records, and f) re-validation. DRAs that produce/ distribute or have their own
test facilities must 1) identify, where appropriate, the product by suitable means during
product realization; and 2) identify the product status with respect to monitoring and
measurement requirements throughout product realization. DRAs may require that
manufacturers of herbal products have the following where necessary and feasible: a)
chemically defined reference active crude extract (RACE), b) chemically defined marker
substance (DMS) and TLC, HPLC or GC-MS fingerprints of RACE and DMS. Since traceability is a
key requirement, DRAs need to enforce manufacturers to have the means of controlling the
unique identification of the product at various stages of development, and of course maintain
records.
Obviously, DRAs that produce/ distribute products or run test laboratories/ facilities must
exercise care with any customer property under their control. They must record and promptly
report any loss or damage to the customer. NOTE: Customer property may be physical or
otherwise.
As a standard practice, a DRA would: 1) assess and record the validity of prior results if the
equipment/ method are found not to conform to requirements; 2) maintain records of the
results of calibration and verification; and 3) confirm or re-confirm the ability of any software
or programme used for monitoring or measurement before its initial use. To ensure the validity
of results, a DRA would normally:
1. Calibrate and/or verify the measuring equipment at specified intervals or prior to use.
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7.5.5 Preservation of Product
Preservation of product broadly includes: 1) identification,
2) handling,
3) packaging, 4) storage, and 5) protection
7.6 Control of Measuring and
Monitoring Equipment
As may be applicable, a DRA would:
1) Determine the type of monitoring
and measurements to be made,
and the equipment/ method to be
used in providing evidence of conformity
2) Use and control the monitoring and measuring devices
in order to ensure that measurement capability is
consistent with monitoring and measurement
requirements.
2. Calibrate the equipment to national or international standards (or record other appropriate
basis).
3. Adjust or re-adjust as necessary.
4. Identify the measuring equipment in order to determine its calibration status
5. Safeguard equipment from improper adjustments.
6. Protect equipment from damage and deterioration
*The Table is to be studied side by side with contents of ISO 9001:2008 and Table 2, which is on the regulatory re‐
quirements of DRAs.
Table 10. Clause 7 of ISO 9001:2008 in relation to DRAs (Purchasing/ Production/ Control of Equipment).
Clause Title and subtitles, with remarks Salient points/ directing principles/ application to DRAs
8 8 Measurement, analysis and
Improvement
8.1 General
A producing/ distributing DRA would plan and implement
the monitoring, measurement, analysis, and improvement
processes it needs to: 1) demonstrate conformity to
product requirements; 2) ensure conformity of the QMS
to planned arrangements;
and 3) continually improve the effectiveness of the QMS.
Non-producing/ distributing DRAs
must have the ability to ensure that manufacturers/
distributors comply.
8.2 Monitoring and measurement
8.2.1 Customer Satisfaction
DRAs must routinely: 1) monitor information on
customer/ stakeholder perception as to whether it is
meeting
its Mandate; and 2) define the
methods for obtaining and using that information.
8.2.2 Internal Audit
Given the overwhelming importance of measurement, analysis and improvement to the
Mandate of DRAs, a DRA would typically want to be sure, thorough and effective in the
application of clause 8. To ensure effectiveness therefore, the DRA would routinely, or as may
be necessary, determine through planning the need for, use of, and extent of use of applicable
methods, including statistical techniques. DRAs should view customer/ stakeholder perception
as a key performance measurement of its QMS. For producing and/ or distributing DRAs
especially, monitoring customer/ stakeholder perception can be obtained from: 1) customer/
stakeholder satisfaction surveys; 2) customer data on delivered product quality; 3) user opinion
surveys; 4) lost business analysis; 5) compliments; 6) warranty claims; and 7) dealer reports.
For thoroughness and effectiveness a producing/ distributing DRA must: 1) plan the audit
program; 2) consider the status and importance of the audited areas; 3) consider the results of
prior audits; 4) define the audit criteria, scope, frequency, and methods; and 5) select and use
impartial and objective auditors. Non-producing/ distributing DRAs must have the ability to
ensure that manufacturers/ distributors comply.
To institute thoroughness and effectiveness, producing/ distributing DRAs must:
1. Maintain records of the audits and their results.
2. Ensure control of the audited areas.
3. Take actions without undue delay to eliminate detected nonconformities and their causes.
4. Verify through follow-up actions.
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Internal audits must be conducted at planned intervals so
that DRAs can determine if their QMS: 1) conforms to
requirements of ISO 9001:2008; 2) conforms to planned
arrangements as per sub-clause 7.1; and 3) is effectively
implemented and maintained. In order to thoroughly
address staff responsibilities and the requirements
to be met by the audit exercise, DRAs must establish: 1) a
documented procedure for planning audit; 2) a
documented procedure for conducting audits; and 3) a
documented procedure for recording and reporting audit
results.
Again, non-producing/ distributing DRAs must have the ability to ensure that manufacturers/
distributors comply.
NOTE: ISO 19011 (Audit guidance) should be consulted for further enlightenment quality
auditing.
*The Table is to be studied side by side with contents of ISO 9001:2008 and Table 2, which is on the regulatory re‐
quirements of DRAs.
Table 11. Clause 8 of ISO 9001:2008 in relation to DRAs (Monitoring and measurement).
3.4.6. Remediation of a malfunctioning DRA
A national or regional DRA is a critical factor in socioeconomic development and wellbeing
in at least two ways: i) by “guaranteeing the health of the nation” (as trumpeted in NAF‐
DAC’s adverts); and by supporting the emergence of responsible manufacturers of regulat‐
ed products. It is well known that the US-FDA more than any US organization has made the
US the world leader in manufacture of health products. The prominence of India and China
in world drug trade owes much to the vibrancy and relative efficiency of their DRAs. There
is therefore a critical need for DRAs to be vibrant and responsible. The gravity with which
China views the role of her DRA can be gauged by the death sentence passed on the Direc‐
tor General in 2007 for accepting a bribe [15].
Clause Title and subtitles, with remarks Salient points/ directing principles/ application to DRAs
8 8.2.3 Monitoring and
Measurement of Processes
1) Apply suitable methods to monitor and, where
applicable, measure the QMS processes.
2) Confirm through these methods
the continuing ability of each process to satisfy its
intended purpose.
3) When the planned results are not achieved, take
correction and corrective action, as appropriate.
8.2.4 Monitoring and
Measurement of Product
Producing/ distributing DRAs need to 1) apply suitable methods for monitoring and measuring
QMS processes; and 2) confirm through these methods the continuing ability of each process to
satisfy its intended purpose.
Non-producing/ distributing DRAs must have the ability to ensure that manufacturers/
distributors comply.
NOTE: When determining “suitable” methods, consideration is given to the type and extent of
monitoring or measurement for each process in relation to its impact on product conformity and
on the effectiveness of the QMS.
To better fulfil their Mandate producing/ distributing DRAs must 1) monitor and measure product
characteristics so as to verify if product requirements are being met; 2) carry out the monitoring
and measurements at the appropriate stages of product realization in accordance with planned
arrangements; and 3) maintain evidence of conformity with the acceptance criteria.
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1) Monitor and measure product characteristics to
verify if product requirements are being met.
2) Carry out the monitoring and measuring at the
appropriate stages
of product realization in accordance with planned
arrangements (see 7.1).
3) Maintain evidence of conformity with the
acceptance criteria.
4) Record the person responsible for authorizing
release of product for delivery to the customer.
8.3 Control of nonconforming
product
DRAs must: 1) Ensure any nonconforming product is
identified and controlled to prevent its unintended use
or delivery.
2) Establish a documented procedure to define the
controls and the related responsibilities/authorities for
dealing with nonconforming product.
DRAs must maintain records of the nature of the
nonconformity, and any subsequent actions, (including
any concessions). When the
nonconformity is corrected, DRAs
must re-verify it to prove or show evidence of
conformity.
It is again stressed that non-producing/ distributing DRAs must have the ability to ensure that
manufacturers/ distributors comply.
DRAs must ensure that product release and service delivery cannot proceed until all planned
arrangements (see 7.1) have been satisfactorily completed, unless otherwise approved by a
relevant authority, and where applicable, the customer.
Where applicable, DRAs must deal with the nonconforming product by one or more of the
following ways:
1. Take action to eliminate the detected nonconformity.
2. Authorize its use, release, or acceptance by concession.
3. Take action to preclude its original intended use or application.
4. Take action appropriate to the effects, or potential effects, of the nonconformity when
nonconforming product is detected after delivery or use has started
To better fulfil their Mandate, DRAs must: 1) Ensure that any nonconforming product is identified
and controlled to prevent its unintended use or delivery. 2) Establish a documented procedure to
define the controls and related responsibilities and authorities for dealing with nonconforming
product.
*The Table is to be studied side by side with contents of ISO 9001:2008 and Table 2, which is on the regulatory re‐
quirements of DRAs. Although a DRA may not possess certain facilities for measurements and monitoring, it should
possess the ability or the means necessary to ensure that manufacturers/ distributors possess and use them in accord‐
ance with approved QMS guidelines.
Table 12. Clause 8 of ISO 9001 in relation to DRAs (Product characteristics/ Control of nonconformities).
In Nigeria, the entire NAFDAC Management was sacked on alleged acts of corruption in 2000.
It seems to us that the following are essential for a DRA to perform optimally:
1. The laws creating/ amending a DRA should be well articulated as is the case with the US-
FDA.
2. DRAs should be so well funded as not to rely on a plethora of frivolous fees as with NAF‐
DAC.
3. Staffing of DRAs must be transparent - competence and integrity must be the decisive
criteria.
4. DRAs should be audited frequently, at least yearly or twice yearly.
5. DRAs should have a Board of Governors to whom the Management reports.
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6. Parliamentary health committees should view DRAs as critical to socioeconomic well‐
being of the nation.
Clause Title and subtitles, with remarks Salient points/ directing principles/ application to DRAs
8 8.4 Analysis of data
Whether producing/ distributing or not, as a rule,
DRAs must determine, collect, and analyze appropriate
data to demonstrate the suitability and effectiveness of
their QMS, as well as, evaluate where continual
improvement of the QMS can be made.
DRAs cannot enforce compliance among
manufacturers/ distributors in an aspect of quality
management in which they are themselves deficient.
8.5 Improvement
8.5.1 Continual Improvement
8.5.2 Corrective Action
The standard practice for organizations is that:
1. Wherever a nonconformity or breach is detected,
corrective action must be taken to eliminate the cause
of the nonconformity and to prevent its recurrence.
2. Wherever corrective action is taken by an
organization, such action must be such as is
appropriate to the
effects of the problem caused by the nonconformity or
breach.
8.5.3 Preventive Action
Organizations must:
1. Determine in advance the action
that needs to be taken to eliminate
the causes of potential non-
conformity, in order to prevent its occurrence.
2. Ensure that preventive actions are appropriate to
the anticipated effects of the potential problem.
DRAs should as a matter of practice:
1. Include the primary data generated by monitoring and measuring activities, and from other
relevant sources in their analyses.
2. Analyze such primary data to provide secondary data on:
a. Customer satisfaction as per 8.2.1.
b. Conformity to product requirements as per 8.2.4.
c. Characteristics and trends of processes and products, including opportunities for preventive
action as per 8.2.3, 8.2.4, and 8.5.3.
d. Suppliers as per 7.4
DRAs are to continually improve the effectiveness of their QMS through:
1. Quality policy
2. Quality objectives
3. Audit results
4. Analysis of data
5. Corrective and preventive action
6. Management review
For thoroughness and effectiveness, DRAs must establish a documented procedure (SOP) for
corrective action. Such a procedure must define requirements to:
1. Review nonconformities (including customer complaints).
2. Determine the causes of nonconformities.
3. Evaluate the need for actions to prevent recurrence.
4. Determine and implementing the needed action.
5. Maintain records of the results of the action taken.
6. Review the effectiveness of corrective action taken
For thoroughness and effectiveness, DRAs must establish a documented procedure for
preventive action. Such a procedure must define requirements to:
1. Determine potential nonconformities and their causes.
2. Evaluate the need for actions to prevent occurrence.
3. Determine and implementing the needed action.
4. Maintain records of the results of the action taken.
Review the effectiveness of preventive action taken
*The Table is to be studied side by side with contents of ISO 9001:2008 and Table 2, which is on the regulatory re‐
quirements of DRAs. It must be stressed once again that if DRAs are to persuade manufacturers/ distributors to com‐
ply with the provisions of this and other clauses of ISO 9001:2008 industrial standard, they too must be conversant
with and adept in them.
Table 13. Clause 8 of ISO 9001:2008 in relation to DRAs (Analysis of data/ Improvement).
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3.4.7. Further remarks on clauses 7 and 8 of ISO 9001:2008
Although the principles of clauses 7 and 8 apply to all organizations, they are strictly speak‐
ing, the deeds and stuff intended for high profile institutions with elaborate concern and fa‐
cilities for design and R&D, and with tall entrepreneurial ambition. Such organizations
include the most successful pharmaceutical and biotechnology companies of the US, Eu‐
rope, Japan and India; NASA, aircraft manufacturers, international airlines and 5-star hospi‐
tality concerns. However, in as much as DRAs must regulate the work and product of
advanced pharmaceutical manufacturers, the onus is upon the DRAs themselves to be con‐
versant with the entire provisions of these clauses and be as intellectually equipped as the
manufacturer. This explains why it is often desirable that regulators have a stint in both aca‐
demia and industry. In many countries, especially the US and India, top rate biomedical fa‐
cilities/ institutions and personnel are to be found in the following four circles: i) the DRAs
(eg: US-FDA); ii) health research institutions (eg: NIH); iii) the universities/ R&D institutions
patronized by the DRAs; and iv) big transnational drug manufacturers (eg: Pfizer). We once
again refer to the Nigeria polio vaccine controversy of the late 1990s/ early 2000s mentioned
earlier, and ask the following question: When a DRA produces or distributes product as is
the case in many developing economies, who regulates the DRA? Can subsequent revisions
of ISO 9001or some other ISO standard provide an answer?
4. Conclusions
It is evident from the foregoing that all the eight clauses of ISO 9001:2008 apply to the Man‐
date of DRAs. However, most of what appears in clauses 7 and 8, the lengthiest of the claus‐
es, relates more pertinently to high stake pharmaceutical manufacturers that have elaborate
R&D than they do to the average DRA, which nevertheless should be thoroughly acquaint‐
ed with the clauses. Some DRAs like the US-FDA and EMEA that have advance laboratories
or access to such or that heavily fund R&D must be guided by the rigorous provisions of
clauses 7 and 8. Needless to say, those DRAs that produce/ distribute products must be simi‐
larly guided to the extent of their relevance to the scope and size of their operations. The US-
FDA, Japan’s Ministry of Health and Social Services and EMEA are certified to appropriate
performance standards and are known for their efficiency. By contrast NAFDAC and other
developing national DRAs are not similarly certified and are less well known for efficiency,
considering the rampancy of counterfeit drugs and other ills in their drug delivery systems.
The DRAs of China, India and Southeast Asian countries compare quite well in many as‐
pects with those of Europe, Canada and the US, and are by far more efficient than those of
many African and South American countries. From the foregoing, and in view of the histori‐
cal and international dimensions of phytotherapy, especially its galloping global patronage
in recent times [1,2,11,12], it is necessary that there to be a minimum global standard to
which DRAs should be certified. We propose ISO 9001 because of its global popularity, ap‐
plicability and suitability. The standard provides the general climate for DRAs to efficiently
discharge their Mandate. We project that a carefully planned application of ISO 9001 to
herbal drug regulation will improve the production, distribution and usage of herbal drugs.
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It will also boost the economy of developing economies that rely to a large extent on herbal
drugs. But since the DRAs of many developing economies produce/ distribute certain prod‐
ucts, there is a need for subsequent revisions of ISO 9001 to take cognisance of the question
of who regulates the regulator that produces/ distributes? In the meantime we recommend
that the Minister/ Secretary of Health and/ or the Parliamentary Committees of Health take
note of this significant lacuna.
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